Evaluation of human leukocyte antigen expression in patients with prostate cancer.
The aim of this prospective study was to evaluate the possible relationship between human major histocompatibility antigens [human leukocyte antigen (HLA)] and prostatic adenocarcinoma. This clinical study was performed in 30 patients with histologically proven prostatic adenocarcinoma and 102 healthy men. HLA A, B and DR groups were evaluated in all patients. Of the HLAs examined, A2, A10, A28, A14, DR6, DR7 and DR9 were found to be accumulated significantly in patients with prostatic cancer in comparison with the healthy subjects. Apart from HLA A2 and DR7, the relative risk has been found to be over 2 in patients demonstrating these antigens. Although there was a statistically significant difference with respect to HLA accumulation between patients with prostate cancer and healthy subjects, larger series of patients including other parameters are needed.